Watson Confirms LUMIGAN and LATISSE Patent Challenges
Watson Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed that its subsidiary, Watson Laboratories, Inc., filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bimatoprost Ophthalmic Solution, 0.01% and Bimatoprost Ophthalmic Solution, 0.03%. Watson's ANDA products are generic versions of Allergan, Inc.'s (NYSE: AGN ) LUMIGAN® 0.01% and LATISSE® products, respectively.
LUMIGAN® 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. LATISSE® is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness and darkness.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.